
Cosmo Bio Company,Limited
3386.TJPXHealthcareMedical - Diagnostics & Research
Latest quote
¥1,250
−¥4.00 · -0.32%
3386.T company overview
Regular session · JST · Market data may be delayed.
Company profile
Company websiteCosmo Bio Company, Limited is a key player in the life science research sector, involved in the global import, export, manufacturing, marketing, and distribution of essential biotools. Their extensive product line includes biochemical reagents, specialized kits, scientific instruments, analytical software, and diagnostic products. Among their research reagents, they offer a wide spectrum such as antibodies, antigens, bioactive substances, enzymes, peptides, amino acids, various chemicals, carbohydrates, lipids, and components derived from viruses and bacteria. They also provide crucial detection reagents, cell and tissue culture systems, and gene analysis solutions. In terms of instrumentation, Cosmo Bio supplies electrophoresis apparatuses, cell culture labware, gene manipulation systems, and data analysis software. Beyond products, the company delivers valuable services like drug discovery support, custom research, and clinical diagnostics. A significant part of their operation involves the development and manufacturing of proprietary cell and cell culture products. This includes a range of specialized cells such as adipose tissue, bone, cartilage, tooth, pancreas, liver function, cardiovascular, immune, and mesenchymal stem cells, in addition to feeder cells, tumor cell lines, coating reagents, and macrophage-related products. They also produce various assay kits for measurement, staining, detection, and purification. Furthermore, they offer specialized biotechnology research equipment, including constant-temperature transport containers, aluminum block heat insulation devices, and dew condensation prevention glass plates, alongside consigned services for custom peptide synthesis and antibody production. Serving a diverse clientele of laboratories, research institutes, and life science education and testing organizations, Cosmo Bio distributes its products through its own outlets in Japan and an international network of sales agents. The company was founded in Tokyo, Japan, in 1978, where its headquarters remain.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- Headquarters
- JP
- CEO
- Norihiko Shibayama
- Listed since
- Sep 27, 2005
- Employees
- 182
Market position
Day range
Current ¥1,250
52-week range
Current ¥1,250
- Open
- ¥1,254
- Previous close
- ¥1,254
- Volume
- 700
- 0.15× average
- Average volume
- 4.57K
- Average daily volume
- Market cap
- 7.09B JPY
- Beta
- 0.17
- Market reference 1
- 50-day average
- ¥1,246.66
- +0.27% above average
- 200-day average
- ¥1,285.94
- -2.79% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 4.69B JPY
- P/E (TTM)
- 19.49×
- P/B (TTM)
- 0.73×
- P/S (TTM)
- 0.63×
- EV / EBITDA
- 9.21×
- Earnings yield
- 4.53%
- Free cash flow yield
- 4.94%
- Dividend yield
- 4.00%
Profitability & efficiency
- Gross margin
- 34.38%
- Operating margin
- 3.09%
- Net margin
- 3.22%
- Return on equity
- 3.58%
- Return on assets
- 2.65%
- Return on invested capital
- 2.01%
Financial health
- Debt / equity
- 0.08×
- Current ratio
- 5.23×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 10.77B JPY | 10.04B JPY | 9.34B JPY | 9.55B JPY | 9.23B JPY |
| Cost of goods sold | 7.06B JPY | 6.71B JPY | 6.09B JPY | 6.11B JPY | 5.57B JPY |
| Gross profit | 3.7B JPY | 3.33B JPY | 3.25B JPY | 3.44B JPY | 3.66B JPY |
| Research and development | — | 83M JPY | 73M JPY | 82M JPY | 70M JPY |
| Selling, general, and administrative | 3.36B JPY | 2.93B JPY | 2.73B JPY | 2.54B JPY | 2.54B JPY |
| Operating expenses | 3.36B JPY | 3.01B JPY | 2.73B JPY | 2.62B JPY | 2.61B JPY |
| Interest income | 13M JPY | 9M JPY | 6M JPY | 3M JPY | 3M JPY |
| Depreciation and amortization | 167M JPY | 136M JPY | 148M JPY | 141M JPY | 166M JPY |
| Operating income | 342M JPY | 318M JPY | 519M JPY | 816M JPY | 1.05B JPY |
| Net income | 336M JPY | 262M JPY | 442M JPY | 517M JPY | 737M JPY |
Company facts updated Aug 24, 2026.
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
¥50.00
2025 complete year+38.9% since 2021
2026 partial: ¥25.00
¥36.00
2,021
¥36.00
2,022
¥30.00
2,023
¥50.00
2,024
¥50.00
2,025
¥25.00
2,026*
* Partial calendar year in the available dividend history.
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
DividendUpcoming | Dec 29, 2026 | ¥25.00Semi-Annual | Dec 31, 2026 | Dec 29, 2026 |
Dividend | Jun 29, 2026 | ¥25.00Semi-Annual | Jun 30, 2026 | Sep 10, 2026 |
Dividend | Dec 29, 2025 | ¥25.00Semi-Annual | Dec 31, 2025 | Mar 25, 2026 |
Dividend | Jun 27, 2025 | ¥25.00Semi-Annual | Jun 30, 2025 | Sep 10, 2025 |
Dividend | Dec 27, 2024 | ¥36.00Semi-Annual | Dec 31, 2024 | Mar 26, 2025 |
Dividend | Jun 27, 2024 | ¥14.00Semi-Annual | Jun 30, 2024 | Sep 10, 2024 |
Ex-dividend Dec 29, 2026
¥25.00
Semi-Annual
Record Dec 31, 2026 · Payment Dec 29, 2026
Ex-dividend Jun 29, 2026
¥25.00
Semi-Annual
Record Jun 30, 2026 · Payment Sep 10, 2026
Ex-dividend Dec 29, 2025
¥25.00
Semi-Annual
Record Dec 31, 2025 · Payment Mar 25, 2026
Ex-dividend Jun 27, 2025
¥25.00
Semi-Annual
Record Jun 30, 2025 · Payment Sep 10, 2025
Ex-dividend Dec 27, 2024
¥36.00
Semi-Annual
Record Dec 31, 2024 · Payment Mar 26, 2025
Ex-dividend Jun 27, 2024
¥14.00
Semi-Annual
Record Jun 30, 2024 · Payment Sep 10, 2024
3386.T peers
Continue in GoAI
Research 3386.Tresearch.disclaimer





